Popular Articles
Cellulite Cream

Novavax Completes Enrollment Of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
Novavax, Inc. (Nasdaq: NVAX) announced that enrollment has been completed in the second Phase II clinical trial of its trivalent virus-like particle (VLP) seasonal influenza vaccine. This Phase IIa randomized, placebo-controlled study is evaluating a VLP vaccine against the H3N2, H1N1, and B influenza strains that circulated in the 2008-2009 influenza season. This clinical trial represents another step in the development of Novavax"s VLP seasonal influenza vaccine, allowing further evaluation of safety and immunogenicity of a broad range of vaccine doses against a new set of influenza strains. As announced in December of 2008, the first Phase II study evaluated a trivalent VLP vaccine against the seasonal influenza strains that circulated in the 2005-2006 influenza season.
generic viagra online
Economist Examines 'Snail-Fever' In China
The Economist examines schistosomiasis in China. The disease, which is also called snail-fever, is the "world"s second-most prevalent tropical disease after malaria, affecting 207 million people of whom 726,000 are Chinese, according to the most recent official figures, from 2004," the Economist reports.
News of the day
AlphaRx Reports Positive Preclinical Data On GAI-122 Against Liver Disease
AlphaRx Inc. (OTCBB: ALRX) reported positive preclinical results on GAI-122 injectable nano-emulsion in multiple models of acute hepatitis, an inflammatory liver disease.
Sexual Health

Evidence Of Harm Has Been Linked To Various Vaccines Challenging Prevailing Public Recommendations

Researchers at the Mayo Clinic set out to determine whether the flu vaccine was effective in reducing the number of hospitalizations for all children, and especially the ones with asthma. The study involved 263 children who were evaluated from six months to 18 years of age, each of whom had had laboratory-confirmed influenza between 1996 to 2006. The investigators determined which children had and had not received the flu vaccine, their asthma status, and who did and did not require hospitalization. Records were reviewed for each subject with influenza-related illness, for flu vaccination preceding the illness, and hospitalization during that illness. "They found that children who had received the flu vaccine had three times the risk of hospitalization, as compared to children who had not received the vaccine. In asthmatic children, there was a significantly higher risk of hospitalization in subjects who received the TIV, as compared to those who did not (p= 0.006)." So, will these disturbing findings--namely, ineffectiveness of the TIV vaccine coupled with evidence of harm--lead the Center for Disease Control and the American Academy of Pediatrics (AAP) to rescind their recommendation for annual influenza vaccination for all children aged six months to 18 years? Or will our public health policy continue to be guided by the entrenched pharmaceutical industry? When evidence suggests that current vaccine recommendations are harming children it is unethical to delay issuing a cautionary advisory by invoking "more studies are needed" to delay action. Public health policy should be guided by the precautionary principle--"Above all, do no harm"--not by business interests. American Thoracic Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):